Journal
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
Volume 44, Issue 5, Pages 979-988Publisher
SPRINGER
DOI: 10.1007/s40618-020-01392-5
Keywords
DPP4; Fatty liver
Categories
Funding
- Sapienza University, Italy
- Banca d'Italia Foundation
- Eli Lilly Foundation
- Universita degli Studi di Roma La Sapienza within the CRUI-CARE Agreement
Ask authors/readers for more resources
This study found that NAFLD patients had significantly higher circulating DPP4 activity compared to non-NAFLD patients, and that plasma DPP4 activity correlated with steatosis grade and inflammation. Additionally, multivariate logistic regression analysis showed that higher circulating DPP4 activity was independently associated with NAFLD.
Introduction Dipeptidyl peptidase 4 (DPP4) levels are associated to metabolic and cardiovascular diseases in humans; initial evidence reported a relationship between DPP4 and chronic liver diseases. Aim of this study was to investigate hepatic and systemic DPP4 levels/activity in relation to NAFLD/NASH in individuals with and without metabolic disease. Methods We recruited fifty-two obese individuals undergoing bariatric surgery and intra-operative liver biopsy at Sapienza University, Rome, Italy. The association between DPP4 levels/activity and NAFLD was also evaluated in 126 non-obese individuals recruited in the same setting. Results NAFLD patients had significantly higher circulating DPP4 activity than no-NAFLD in both the obese and non-obese cohorts; plasma DPP4 activity and levels linearly correlated with steatosis grade and inflammation at the liver biopsy. HepaticDPP4mRNA was not associated to either its circulating levels/activity or NAFLD. In the multivariate logistic regression analysis on all the study participants (n = 178), higher circulating DPP4 activity was associated with NAFLD independently of potential confounders with OR (95% CI): 3.5 (1.2-10.21),p = 0.022. Conclusions This study demonstrates the coexistence of increased plasma DPP4 levels and activity in NAFLD. Circulating DPP4 measurement may represent a novel cost-effective strategy for NAFLD/NASH risk stratification and a potential tool for monitoring disease's progression in established NAFLD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available